← Patent-cliff monitor small molecule RINVOQ UPADACITINIB
Loss of exclusivity March 2038 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name RINVOQ Active ingredient UPADACITINIB Strength 15MG Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval August 2019 Marketing status RX
Listed patents Patent Expires Type 11607411 March 2038 use U-3341 11564922 March 2038 use U-3624 11365198 October 2036 use U-3275 11773106 October 2036 use U-3371 11976077 October 2036 use U-3298 11524964 October 2036 use U-3371 11795175 October 2036 use U-3255 11535624 October 2036 use U-3255 11535625 October 2036 use U-3298 12365689 October 2036 use U-3945 11993605 October 2036 use U-3946 11993606 October 2036 use U-3487 11767326 October 2036 use U-3298 10995095 October 2036 use U-3298 10597400 October 2036 use U-3255 11780848 October 2036 use U-3371 12570664 October 2036 use U-4454 11198697 October 2036 product 11661425 October 2036 substance, product 12103933 October 2036 product 11773105 October 2036 substance, product 12110298 October 2036 substance, product 10519164 October 2036 product 11512092 October 2036 use U-3371 11680069 October 2036 substance, product 11186584 October 2036 substance 10981924 October 2036 product 11787815 October 2036 product 12077545 October 2036 product 11780847 October 2036 product 9963459 October 2036 product 11718627 October 2036 substance, product 12110297 October 2036 product 9951080 October 2036 substance, product 10981923 October 2036 substance RE47221 August 2033 substance 8962629 January 2031 substance
Regulatory exclusivity Code Expires ODE-538 April 2032 ODE-481 April 2031 I-966 April 2028 I-946 April 2027 NPP April 2027 I-919 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.